The treatment of polycystic ovary syndrome

Minerva Ginecologica

Volumn 56, Issue 1, 2004, Pages 15-26

  Ajossa, S ^a   Guerriero, S ^a   Paoletti, A M ^a   Orru M ^a   Melis, G B ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Infertility, female; Polycystic ovary syndrome, diagnosis; Polycystic ovary syndrome, therapy

Indexed keywords

CABERGOLINE; CLOMIFENE CITRATE; CYPROTERONE ACETATE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADOTROPIN; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; RECOMBINANT FOLLITROPIN; SPIRONOLACTONE;

ANDROGEN BLOOD LEVEL; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONCEPTION; DIABETES MELLITUS; DIATHERMY; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; HEALTH HAZARD; HIRSUTISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LAPAROSCOPIC SURGERY; LUTEINIZATION; MENSTRUATION DISORDER; OVARY POLYCYSTIC DISEASE; OVULATION; REVIEW; WEIGHT REDUCTION;

ADULT; ALDOSTERONE ANTAGONISTS; ANDROGEN ANTAGONISTS; CARDIOVASCULAR DISEASES; CLOMIPHENE; CYPROTERONE ACETATE; DIABETES COMPLICATIONS; DOPAMINE AGONISTS; ERGOLINES; FEMALE; FINASTERIDE; FLUTAMIDE; FOLLICLE STIMULATING HORMONE; GONADOTROPINS; HIRSUTISM; HUMANS; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; INSULIN RESISTANCE; METFORMIN; OBESITY; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; SPIRONOLACTONE; WEIGHT LOSS;

EID: 1542289147     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR editors. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications; 1992.p.377-84.
2. Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotrophin-releasing hormone. Lancet 1985;2:1375-9.
3. Winters SJ, Talbott E, Guzick DS, Zboroski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000;73:724-9.
4. Sherman BM, Korenman ST. Measurement of serum LH, FSH, estradiol and progesterone in disorder of the human menstrual cycle: the inadequate luteal phase. J Clin Endocrinol Metab 1974;39:145-9.
5. Kerin JF, Liu JH, Philippou G, Yen SS. Evidence for an hypothalamic site of action of clomiphene citrate in women. J Clin Endocrinol Metab 1985;61:265-8.
6. Adaghi EY. Clomiphene citrate: mechanisms and sites of action: a hypothesis revisited. Fertil Steril 1984;42:331-44.
7. Hammond MG, Halme JK, Talbert LM. Factors affecting the pregnancy rate in clomiphene citrate induction of ovulation. Obstet Gynecol 1983;62:196-202.
8. Lobo RA, Gysler M, March CM. Clinical and laboratory predictors of clomiphene responses. Fertil Steril 1982;37:168-74.
9. Garcia J, Jones GS, Wentz AC. The use of clomiphene citrate. Fertil Steril 1977;28:707-17.
10. Shepard MK, Balmaceda JP, Leija CG. Relationship of weight to successful induction of ovulation with clomiphene citrate. Fertil Steril 1979;36:641-5.
11. Gysler M, March CM, Mishell DM Jr, Bailey EJ. A decade's experience with individualized clomiphene citrate treatment regimen including its effect on the post-coital test. Fertil Steril 1982;37:161-7.
12. Speroff L, Glass RH, Kase NG. Anovulation and the polycystic ovary syndrome. Clinical gynaecologic endocrinology and infertility. 6th ed. Baltimore: Williams and Wilkins; 1999.
13. Parsanezhad ME, Alborzi S, Motazedian S, Omrani G. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial. Fertil Steril 2002;78:1001-4.
14. Edwards A, Torrot L, Plouffe JR, Kieth H, Randall H, Darrel W et al. Ovulation induction in clomiphene-resistant anovulatory women with normal DHEAS levels: beneficial effects of the addition of dexamethasone during the follicular phase. Fertil Steril 1996;66:3484-6.
15. Baird DT. A model for follicular selection and ovulation: lessons from superovulation. J Steroid Biochem 1987;27:15-23.
16. Dor J, Shulman A, Levran D, Ben-Rafael Z, Rudak E, Mashiach S. The treatment of patients with polycystic ovarian sindrome by in vitro fertilization and embryo transfer: a comparison of results with those of patients of tubal inferility. Hum Reprod 1990;5:816-8.
17. Tarlatzis BC, Grimbizis G. The significance of high follicular phase luteinizing hormone levels in the treatment of women with polycystic ovarian syndrome by in vitro fertilization. J Assist Reprod Genet 1997;14:1-4.
18. Shulman A, Dor J. In vitro fertilization treatment in patients with polycystic ovaries. J Assist Reprod Genet 1997;14:7-10.
19. MacDougall MJ, Tan SL, Balen A, Jacobs HS. A controlled study comparing patients with a without polycystic ovaries undergoing in vitro fertilization. Hum Reprod 1993;8:233-7.
20. Franks S. The treatment of patients with polycystic ovaries undergoing IVF. J Assist Reprod Genet 1997;14:12-4.
21. Kamrava MM, Seibel MM, Berger MJ, Thompson I, Taymor ML. Reversal of persisten anovulation in polycystic ovarian disease by administration of low dose follicle-stimulating hormone. Fertil Steril 1982;37:520-3.
22. Brown JB. Pituitary control of ovarian function-concept derived from gonadotrophin therapy. Aust N Z J Obstet Gynaecol 1978;18:46-54.
23. Ben-Rafael Z, Levy T, Shoemaker J. Pharmacokinetics of follicle-stimulating hormone: clinical significance. Fertil Steril 1995;63:689-700.
24. Homburg R Levy T, Ben-Rafael Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for ovulation induction associated with polycystic ovary syndrome. Fertil Steril 1995;63:729-33.
25. Grigoriou O, Antoniou G, Antonaki V, Patsouras C, Zioris C, Karakitsos P. Low dose follicle stimulating hormone treatment for polycystic ovarian disease. Int J Gynecol Obstet 1996;52:55-9.
26. Fauser BC, Donderwinkel PFJ, Schoot DJ. The Step-down principle in gonadotropin treatment and the role of GnRH analogues. Baillieres Clin Obstet Gynecol 1993;7:309-30.
27. Mizunuma H, Takagi T, Yamada K, Andoh K, Ibuki I, Igarashi M. Ovulation induction by step-down administration of purified urinary follicle-stimulating hormone in patients with polycystic ovarian syndrome. Fertil Steril 1991;55:1195-6.
28. Andoh K, Mizunuma H, Liu X, Kamijo T, Yamada K, Ibuki Y. A comparative study of fixed-dose, step-down, and low-dose step-up regimens of human menopausal gonadotropin for patients with polycystic ovary syndrome. Fertil Steril 1998;70:840-6.
29. Van Dessel H, Donderwinkel P, Coelingh Bennink H, Fauser BC. First established pregnancy and birth after induction of ovulation with recombinant FSH in PCOS. Hum Reprod 1994;9:55-6.
30. Out HJ, Mannaerts BM, Driessen SG, Coelingh Bennink HJT. A prospective, randomised, assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon vs Metrodin) in in vitro fertilization. Hum Reprod 1995;10:2534-40.
31. Coelingh Bennink HJT, Fauser BC, Out HJ. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic chronic anovulation: a prospective, multicenter, assessor-blind, randomised, clinical trial. Fertil Steril 1998;69:19-25.
32. Calaf Alsina J, Ruiz Balda JA, Romeu Sarrio A, Caballero Fernandez V, Cano Trigo I, Gomez Parga JL et al. Ovulation induction with a starting dose of 50IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. BJOG 2003;110:1072-7.
33. Van Wely M, Bayram N, van der Veen F. Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review. Hum Reprod 2003;18:1143-9.
34. Shally AV, Kastin AJ, Arimura A. Hypothalamic FSH and LH-regulating hormone: structure, physiology, and clinical studies. Fertil Steril 1971;22:703-21.
35. Homburg R, Eshel A, Kilborn J, Adams J, Jacobs HS. Combined luteinising hormone-releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries. Hum Reprod 1990;5:32-5.
36. Dodson WC, Hughes Jr CL, Yancy SE, Haney AF. Clinical characteristics of ovulation induction with human menopausal gonadotrophins with and without leuprolide acetate in polycystic ovary syndrome. Fertil Steril 1989;52:915-8.
37. McDougal MJ, Tan SL, Balen A, Jacobs HS. A controlled study comparing patients with and without polycystic ovaries undergoing in vitro fertilisation. Hum Reprod 1993;7:233-7.
38. Hughes EC, Collins J, Vandekerckhove P. Gonadotrophin-releasing hormone analogue as an adjunct to gonadotrophin therapy for clomiphene resistant polycystic ovarian syndrome. Cochrane Database Syst Rev 2000;2:CD000097.
39. Cardone VS. GnRH antagonists for treatment of polycystic ovarian syndrome. Fertil Steril 2003;80Suppl 1 S25-31; discussion S32-4.
40. Burger CW, Korsen TJ, Hompes PG, Van Kessel H, Schoemaker J. Ovulation induction with pulsatile luteinizing releasing hormone in women and clomiphene-citrate-resistant polycystic ovary-like disease: clinical results. Fertil Steril 1986;46:1045-54.
41. Gibson M. Reproductive health and polycystic ovary syndrome. Am J Med 1995;98:67S-75S.
42. Buttram V, Vaguero C. Post-ovarian wedge resection adhesive disease. Fertil Steril 1975;26:874-6.
43. Toaff R, Toaff ME, Peyser MR. Infertility following wedge resection of the ovaries. Am J Obstet Gynecol 1976;124:92-6.
44. Campo S, Garcea N, Caruso A, Siccardi P. Effect of celioscopic wedgw resection in patients with polycystic ovaries. Gynecol Obstet Invest 1983;15:213-22.
45. Pirwany I, Tulandi T. Laparoscopic treatment of polycystic ovaries: is it time to relinquish the procedure? Fertil Steril 2003;80:241-51.
46. Rossmanith WG, Keckstein J, Spatzier K, Lauritzen C. The impact of ovarian laser surgery on the gonadotrophin secretion in women with polycystic ovarian disease. Clin Endocrinol (Oxf) 1991;34:23-30.
47. Gjonnaess H. Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome. Fertil Steril 1998;69:97-101.
48. Abdel GA, Khatim MS, Alnaser HM, Mowafi RS, Shaw RW. Ovarian electrocautery. Responders versus non-responders. Gynecol Endocrinol 1993;7:43-8.
49. Gjonnaess H. Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results. Acta Obstet Gynecol Scand 1994;73:407-12.
50. Kovacs G, Bukler H, Bangah M, Outch K, Burger H, Healy D et al. Treatment of anovulation due to polycystic ovarian syndrome by laparoscopic ovarian electrocautery. Br J Obstet Gynaecol 1991;98:30-5.
51. Tozer AJ, Al Shawaf T, Zosmer A, Hussain S, Wilson C, Lower AM et al. Does laparoscopic ovarian diathermy affect the outcome of IVF-embryo transfer in women with polycystic ovarian syndrome? A retrospective comparative study. Hum Reprod 2001;16:91-5.
52. Greenblatt EM, Casper RF. Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate. Fertil Steril 1993;60:766-70.
53. Mais V, Ajossa S, Piras B, Guerriero S, Marongiu D, Melis GB. Prevention of de novo adhesion formation after laparoscopic myomectomy: a randomized trial to evaluate the effectiveness of an oxidized regenerated cellulose absorbable barrier. Hum Reprod 1995;10:3133-5.
54. Mais V, Ajossa S, Marongiu D, Peiretti RF, Guerriero S, Melis GB. Reduction of adhesion reformation after laparoscopic endometriosis surgery: a randomized trial with an oxidized regenerated cellulose absorbable barrier. Obstet Gynecol 1995;86:512-5.
55. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
56. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M et al. Metformin effects on clinical features, endocrine and metabolic profile, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-46.
57. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4.
58. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54.
59. Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003;361:1894-901.
60. De Leo V, la Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced oculation in women with polycystic ovary syndrome. Fertil Steril 1999;72:282-5.
61. Pirwany IR, Yates RWS, Cameron IT, Fleming R. Effects of the insulin sensitising drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhea. Hum Reprod 1999;14:2963-8.
62. Fleming R, Hopkinson ZE, Wallace M, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomised double blind placebo-controlled trial. J Clin Endocrinol Metab 2002;87:1-6.
63. Barnes RB, Lobo RA. Central opioid activity in polycystic ovary syndrome with or without dopaminergic modulation. J Clin Endocrinol Metab 1985;61:779-82.
64. Paoletti AM, Cagnacci A, Soldani R, Orru M, Ajossa S, Pittorra G et al. Evidence that an altered prolactin release is consequent to abnormal ovarian activity in polycystic ovary syndrome. Fertil Steril 1995;64:1094-8.
65. Paoletti AM, Cagnacci A, Depau GF, Orrù M, Ajossa S, Melis GB. The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril 1996;66:527-32.
66. Ajossa S, Paoletti AM, Guerriero S, Mannias M, Melis GB. Effect of chronic administration of cabergoline on uterine perfusion in women with polycystic ovary syndrome. Fertil Steril 1999;71:314-8.
67. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
68. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000;21:347-62.
69. Randal VA. Androgens and human hair growth. Clin Endocrinol 1994;40:439-57.
70. Gilling-Smith C. Hirsutism. Current Obstet Gynaecol 2002;12:144-9.
71. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profile in adoloscents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 2002;77:919-27.
72. Azziz R, Ochoa TM, Bradley Jr EL, Potter HD, Boots LR. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomised study. J Clin Endocrinol Metab 1995;80:3406-11.
73. Pazos F, Escobar-Morreale HF, Balsa J, Sancho JM, Varela C. Prospective randomized study comparing the long-acting gonadotrophin-releasing hormone agonist triptorelin, flutamide, and ciproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertil Steril 1999;71:122-8.
74. Lashen H. Use of LHRH agonists in polycystic ovary syndrome. Rev Gynecol Pract 2003;3:127-31.
75. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 2003;101:995-1007.
76. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F et al. Comparison of spironolactone, flutamide and finasteride efficacy in the treatment of hirsutism: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85:89-94.
77. Venturoli S, Marescalchi O, Colombo FM, Macrelli S, Ravaioli B, Bagnoli A et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketonazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999;84:1304-10.
78. Erenus M, Gurbuz O, Durmusoglu F, Demircay Z, Pekin S. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Fertil Steril 1994;61:613-6.
79. Ajossa S, Guerriero S, Paoletti AM, Orrù M, Melis GB. The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome. Fertil Steril 2002;77:1136-40.
80. Rittmaster RS. Finasteride. New Engl J Med 1994;330:120-5.
81. Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR. Treatment of hirsutism: comparison between different antiandrogens with central and peripheral effects. Fertil Steril 1999;71:445-51.
82. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M. Effect of diet and metformin administration on sex hormone-binding globulin, androgens and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995;80:2057-62.
83. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998;69:691-6.
84. Kolodziejczyk B, Duleba A, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000;73:1149-54.
85. Kelly CJ, Gordon J. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002;147:217-21.
86. Nestler JE. Polycystic ovary syndrome: a disorder for the generalist. Fertil Steril 1998;70:811-2.
87. Barbieri RL, Makris A, Randall W, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986;62:904-10.
88. Cagnacci A, Paoletti AM, Arangino S, Melis GB, Volpe A. Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism. Hum Reprod 1999;14:893-7.
89. Paoletti AM, Cagnacci A, Orrù M, Ajossa S, Guerriero S, Melis GB. Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. Fertil Steril 1999;72:448-53.
90. Diamante-Kandarakis E, Mitrakou A, Hennes MMI, Platanissiotis D, Kaklas N, Spina J et al. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 1995;44:525-31.
91. Sharma A, Atiomo W. Recent development in polycystic ovary syndrome. Curr Obstet Gynecol 2003;13:281-6.